CIK 0001680581 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2024 | FY2023 | FY2019 | |
|---|---|---|---|
| Net income (USD) | -109.9 M | -32.6 M | |
| Diluted EPS (USD/shares) | -1.59 | -2.44 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-08 | S-4/A | S-4/A | |
| 2026-09-02 | 144 | 144 | |
| 2026-09-02 | S-4 | S-4 | |
| 2026-08-17 | 425 | 425 | |
| 2026-08-17 | 425 | 425 | |
| 2026-08-17 | 425 | 425 | |
| 2026-08-17 | 8-K | 8-K items 1.01,3.02,5.01,5.02,7.01,9.01 | 2026-08-16 |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-14 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-10 | 8-K | 8-K items 5.02 | 2026-08-07 |
| 2026-08-03 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-07-30 | 10-Q | 10-Q | 2026-06-30 |
| 2026-07-28 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-07-20 | 4 | 4 | 2026-07-16 |
| 2026-07-17 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-07-15 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-07-15 | 4 | 4 | 2026-07-13 |
| 2026-07-15 | 3 | 3 | 2026-07-13 |
| 2026-07-02 | 4 | 4 | 2026-06-30 |
| 2026-07-02 | 4 | 4 | 2026-06-30 |
| 2026-07-02 | 4 | 4 | 2026-06-30 |
| 2026-07-02 | 4 | 4 | 2026-06-30 |
| 2026-07-02 | 4 | 4 | 2026-06-30 |
Forms on file (last 1,000): 4 183, 8-K 84, 3 36, SC 13G/A 35, 10-Q 22, SC 13G 20, SCHEDULE 13G/A 15, 424B5 11. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=FULC (0.002 USD), /gw/filings/filings?ticker=FULC&form=8-K, /gw/filings/facts?ticker=FULC&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange